Eli Lilly and Company

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Neurology, Medication, Astellas Pharma, Pfizer, ALS, Science, Wolfram syndrome, University, FACP, AMX0035, Research, Doctor of Philosophy, MD, Biology, Critical care, Palsy, Drug development, FCCP, Amylyx Pharmaceuticals, Pharmacovigilance, Eli Lilly and Company, CMO, Wolfram, Biotechnology Innovation Organization, Neurodegenerative disease, Medicine, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the addition of Bernhardt G. Zeiher, MD, FCCP, FACP, to its Board of Directors (“Board”).

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the addition of Bernhardt G. Zeiher, MD, FCCP, FACP, to its Board of Directors (“Board”).
  • Most recently, he served as Chief Medical Officer (“CMO”) of Astellas Pharma, where he led early- and late-stage drug development, medical and regulatory affairs, pharmacovigilance, and quality assurance.
  • “Dr.
  • Zeiher brings to the Board his distinguished drug development background in overseeing the approval of 15 medicines, and his first-hand experience as a physician.

Redwire Partners with Eli Lilly and Company on Second Spaceflight Mission to Conduct Additional Research on Chronic Diseases Following Successful Results

Retrieved on: 
Tuesday, March 12, 2024
Aerospace, Satellite, Manufacturing, Other Health, Technology, Audio, Video, Pharmaceutical, General Health, Other Technology, Other Manufacturing, Science, Other Science, Health, Engineering, Research, Redwire, Environment, Drug discovery, Patient, Conditional sentence, Corporation, International Space Station, Life, NASA, RDW, Eli Lilly and Company, PIL, Pharmaceutical industry

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it is partnering with Eli Lilly and Company (Lilly) on a second spaceflight mission using its in-space pharmaceutical manufacturing platform, PIL-BOX.

Key Points: 
  • Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it is partnering with Eli Lilly and Company (Lilly) on a second spaceflight mission using its in-space pharmaceutical manufacturing platform, PIL-BOX.
  • On this second mission (PIL-02)Lilly researchers will be conducting an experiment aimed at accelerating the discovery of novel medicines against chronic diseases.
  • Following the successful results of the PIL-01 experiment, which demonstrated that microgravity benefited insulin crystal growth, Lilly researchers will use the PIL-02 mission to expand their understanding of crystal formulations and how they impact overall drug discovery and development.
  • The PIL-02 experiment will launch onboard SpaceX’s 30th cargo resupply services mission (SpX-30) for NASA to the International Space Station.

STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Optical, General Health, Health, Medical Devices, Clinical Trials, Other Health, Eli Lilly, ICL, Boston Scientific, Growth, AstraZeneca, Presbyopia, Eli Lilly and Company, University, Near-sightedness, Art, Columbia University, Indiana State University, EVO, STAAR, Senior, MBA, Bayer, Campbell University, Nursing credentials and certifications, Marketing, CFA, Waters Corporation, Guidant, Retirement, Arthur Butcher, Economics, Astigmatism, Management

“Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.

Key Points: 
  • “Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry,” said Aimee Weisner, Chair of the Nominating and Governance Committee of STAAR Surgical’s Board of Directors.
  • "Art and Wei also have particular expertise in APAC, the largest market in the world for refractive vision correction.
  • He currently serves as a member of the Board of Directors of Waters Corporation, listed publicly on the New York Stock Exchange.
  • We wish her the best in her future endeavors.”
    With the appointment of Messrs. Butcher and Jiang to the Board, the STAAR Surgical Board is now comprised of eight directors, seven of whom are independent non-employee directors.

Zephyr AI Raises $111 Million in Series A Financing

Retrieved on: 
Wednesday, March 13, 2024
Technology, Clinical Trials, Professional Services, Cardiology, Software, General Health, Health, Data Management, Oncology, Artificial Intelligence, Algorithm, ARU, Gene expression, Entrepreneurship, Eli Lilly and Company, Patient, LLP, Nature, Revolution LLC, Cooley LLP, Medicine, Abstract, AACR, Drug development, Ecosystem, Biomedical sciences, Interim, Machine learning, Collection, Artificial intelligence, Pharmaceutical industry

Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.

Key Points: 
  • Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.
  • We must do better,” said Grant Verstandig, Zephyr AI’s Co-Founder and Executive Chairman.
  • “At Zephyr AI, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data.
  • Cooley LLP served as legal counsel for Zephyr AI.

MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Pharmaceutical, Health, Oncology, MOMA, Georgetown University Law Center, Eli Lilly, Growth, Learning, Science, Partnership, Boehringer Ingelheim, Patient, SVP, Roche, Acquisition, Cancer, IPO, Thought, MBA, Doctor of Philosophy, Investigational New Drug, Johns Hopkins University, Therapy, Heart, Eli Lilly and Company, FDA, Knowledge

MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief business officer.

Key Points: 
  • MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief business officer.
  • “We are thrilled to welcome Jullian to MOMA.
  • She has an exceptional track record of thinking and acting strategically and creatively across different business dimensions, while leading with heart and a passion for mentorship,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA.
  • “Jullian’s expertise is perfectly aligned with MOMA’s business needs at this stage of our growth and positions us more strongly for success.

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.

Retrieved on: 
Monday, March 25, 2024
Curium, FMI, Novartis, Eli Lilly, Face, FAP, Associate, Hospital, Bayer, Cancer, Actinium-225, Medicare, Radiopharmaceutical, Radio, Therapy, Eli Lilly and Company, Government

NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that.

Key Points: 
  • This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead.
  • NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide.
  • With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade.
  • Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade.

CKD Leaders Network Publishes New Thought Piece in Journal of Clinical Medicine

Retrieved on: 
Thursday, March 21, 2024
Research, Disease, FACC, Conditional sentence, TKG, Data science, CKD, Medicine, Patient, Author, Mortality, Manuscript, University, ICMJE, MPH, Network, Chronic kidney disease, Eli Lilly and Company, Multimedia, Marketing, Boehringer Ingelheim, Pharmaceutical industry

NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.

Key Points: 
  • NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network , a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new manuscript in the Journal of Clinical Medicine.
  • "At The Kinetix Group, we are committed to improving care delivery through collaboration and innovation," said Anna Thomas , executive vice president.
  • CKD affects approximately 37 million individuals in the United States.
  • To learn more about CKD Leaders Network initiatives, contact [email protected] .

Next Mission to Space Station Carries Research on Vision Loss Treatments and Earth-Viewing Technology

Retrieved on: 
Wednesday, March 20, 2024
Janus, LEO, B cell, Falcon 9, Commercial Resupply Services, Medication, University, Eli Lilly and Company, MassChallenge, Patient, ISS National Lab, Research, International Space Station, Boeing, 3D, Astrobee, CRS, Life, Butler University, CSIRO, Argus, Arthritis, Laboratory, NASA, ISS, Cartilage, AMD, Therapy, PIL, SpaceX, Redwire, Defense, Health, Communications satellite

CAPE CANAVERAL, Fla., March 20, 2024 /PRNewswire/ -- The next resupply mission to the International Space Station (ISS) will carry more than 40 payloads sponsored by the ISS National Laboratory®, including in-space production applications projects, technology demonstrations, life science experiments, and student-led inquiries. These investigations, launching on SpaceX's 30th Commercial Resupply Services (CRS) mission, funded by NASA, aim to improve life on Earth through space-based research and foster a sustainable economy in low Earth orbit (LEO).

Key Points: 
  • Results from this research could lead to improved therapeutics to treat an array of conditions.
  • A collaboration between Boeing and CSIRO (an Australian government agency responsible for scientific research) will test the ability of a Multi-Resolution Scanner to create 3D maps of the space station.
  • Once ArgUS is installed, it will host multiple payloads on this mission, including SpaceTV-1, an optical video system designed to livestream high-definition views of Earth and the space station.
  • An investigation from biopharmaceutical company Oculogenex will use the space station to test a novel gene therapy to prevent and possibly even reverse vision loss from age-related macular degeneration (AMD).

Circular Genomics Adds Dr. Michael Ackermann, PhD, MBA to its Scientific Advisory Board

Retrieved on: 
Monday, March 18, 2024
Depression, Psychosis, Neurology, ADHD, Entrepreneurship, Biomarker, RNA, Harvard Business School, Fellow, University, Doctor of Philosophy, Senior, Medicine, MBA, Genomics, DSM-IV codes, Fortune 500, SAB, Arrivo, Eli Lilly and Company, Psychiatry

ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ -- Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD, MBA to its Scientific Advisory Board (SAB).

Key Points: 
  • ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ -- Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD, MBA to its Scientific Advisory Board (SAB).
  • Dr. Ackermann brings significant expertise in biopharmaceutical industry including antidepressant drug development to Circular Genomics.
  • Circular Genomics is at the forefront of introducing precision medicine into mental health care.
  • Since 2015, he has been serving as Co-Founder, Board Member, and Chief Business Officer at Arrivo BioVentures LLC.

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."